---
title: Vasopressors
author: Corbin Cox
layout: diseases
last-updated: 2018-12-4
created: 2018-12-4
toc: true
common: false
---

# Vasopressors

Vasopressor Dosing[^jentzer2015]
{: .caption}

| Drug           | Initial Dose                                          | Typical Dose         | Titration q5-15min                                 | Weaning q5-15min     |
| -------------- | ----------------------------------------------------- | -------------------- | -------------------------------------------------- | -------------------- |
| Epinephrine    | 0.02-0.05 mcg/kg/min                                  | 0.005-0.2 mcg/kg/min | 0.02-0.05 mcg/kg/min                               | 0.02-0.05 mcg/kg/min |
| Norepinephrine | 0.01-0.04 mcg/kg/min                                  | 0.04-1 mcg/kg/min    | 0.02-0.04 mcg/kg/min                               | 0.02-0.04 mcg/kg/min |
| Dopamine       | 5-10 (inotropic)<br />&gt; 10 mcg/kg/min (inopressor) | 2-20 mcg/kg/min      | 2-5 mcg/kg/min                                     | 1 mcg/kg/min         |
| Phenylephrine  | 0.1-0.3 mcg/kg/min                                    | 0.1-1.5 mcg/kg/min   | 0.2-0.4 mcg/kg/min                                 | 0.2-0.4 mcg/kg/min   |
| Vasopressin    | 0.01-0.04 U/min                                       | 0.01-0.04 U/min      | No titration                                       | No weaning           |
| Dobutamine     | 2.5-5 mcg/kg/min                                      | 2.5-10 mcg/kg/min    | 2.5-5 mcg/kg/min<br />Alter based on CO/CI or SVO2 | 2.5-5 mcg/kg/min     |
| Milrinone      | 0.25 mcg/kg/min                                       | 0.25-0.75 mcg/kg/min | Alter based on CO/CI or SVO2                       | No weaning           |


Vasopressor Classification[^hollenberg2011]
{: .caption}

| Drug           | Classification | Note                                           |
| -------------- | -------------- | ---------------------------------------------- |
| Epinephrine    | Inopressor     | Can bump lactate d/t &beta; stimulation        |
| Norepinephrine | Inopressor     | Good 1st line choice in almost all situations  |
| Dopamine       | Inopressor     | **Increased mortality in comparison to NE**    |
| Phenylephrine  | Vasopressor    |                                                |
| Vasopressin    | Vasopressor    | No pulmonary constriction                      |
| Dobutamine     | Inodilator     | Increased myocardial O2 demand d/t chronotropy |
| Milrinone      | Inodilator     | Long t<sub>1/2</sub> removing need for weaning |

Vasopressor Hemodynamic Effects[^hollenberg2011]
{: .caption}

| Drug                                           | HR        | Inotropy        | Vasoconstriction | Vasodilation | Dopaminergic |
| ---------------------------------------------- | --------- | --------------- | ---------------- | ------------ | ------------ |
| Epinephrine                                    | ++++      | ++++            | ++++             | +++          | 0            |
| Norepinephrine                                 | +         | ++              | ++++             | 0            | 0            |
| Dopamine (Inotropy)<br />Dopamine (Inopressor) | +<br />++ | +<br />++ - +++ | 0<br />++ - +++  | +<br />0     | ++++<br />++ |
| Phenylephrine                                  | 0         | 0               | +++              | 0            | 0            |
| Vasopressin                                    | 0         | 0               | ++++             | 0            | 0            |
| Dobutamine                                     | ++        | +++ - ++++      | 0                | ++           | 0            |
| Milrinone                                      | +         | +++             | 0                | ++           | 0            |



Vasopressor Receptor Specificity[^overgaard2008]
{: .caption}

| Drug           | &alpha;-1 | &beta;-1 | &beta;-2 | Other                                         |
| -------------- | --------- | -------- | -------- | --------------------------------------------- |
| Epinephrine    | +++++     | ++++     | +++      | -                                             |
| Norepinephrine | +++++     | +++      | ++       | -                                             |
| Dopamine       | +++       | ++++     | ++       | DA                                            |
| Phenylephrine  | +++++     | 0        | 0        | -                                             |
| Vasopressin    | 0         | 0        | 0        | V1 (vasoconstriction)<br />V2 (renal tubules) |
| Dobutamine     | +         | +++++    | +++      | -                                             |
| Milrinone      | 0         | 0        | 0        | PDE-3                                         |




# Push-Dose EPI [^weingart2015]

## Mixing

1.  9mL NS in 10mL syringe
2.  Add 1 mL (100mcg) cardiac epinephrine (0.1mg/mL)
    * **Caution: above is for 1mg/10mL (0.1mg/mL) premix syringes, EPI vials are 1mg/1mL**
3.  Resulting solution is 100mcg/10mL (10mcg/mL) Epinephrine


## Admin

0.5-2**mL** (5-20 mcg) Q2-5min PRN of above solution

Doses last &asymp; 10min

If mixing not possible, give 0.5mL dose of pure cardiac epi (50mcg)

**DO NOT ADMINISTER 1mg EPI TO INDIVIDUALS NOT IN CARDIAC ARREST**

# References
[^weingart2015]: Weingart S. Push-dose pressors for immediate blood pressure control. *Clinical and Experimental Emergency Medicine*. 2015;2(2):131-132. doi:[10.15441/ceem.15.010](https://doi.org/10.15441/ceem.15.010)
[^overgaard2008]: Overgaard CB, Džavík V. Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease. Circulation. 2008;118(10):1047-1056. doi:[10.1161/CIRCULATIONAHA.107.728840](https://doi.org/10.1161/CIRCULATIONAHA.107.728840)
[^jentzer2015]: Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit. Journal of Cardiovascular Pharmacology and Therapeutics. 2015;20(3):249-260. doi:[10.1177/1074248414559838](https://doi.org/10.1177/1074248414559838)
[^hollenberg2011]: Hollenberg SM. Vasoactive Drugs in Circulatory Shock. American Journal of Respiratory and Critical Care Medicine. 2011;183(7):847-855. doi:[10.1164/rccm.201006-0972CI](https://doi.org/10.1164/rccm.201006-0972CI)
